Abstracts Archive - Page 1472 of 2607 - ACR Meeting Abstracts

Abstract Number: 1271 • 2017 ACR/ARHP Annual Meeting
Associations between Systemic Lupus Susceptibility (SLE) Loci and Anti-Phospholipid Antibody (aPL) Positivity in Childhood-Onset SLE (cSLE)
Linda T Hiraki^1,2, France Gagnon³, Earl Silverman², Deborah M. Levy², Sima Abu Alsaoud⁴ and Karl Everett^1,3, ¹Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada, ²Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ³Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ⁴Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Genome-wide association studies have identified nearly 60 susceptibility loci for systemic lupus erythematosus (SLE). However, few studies have investigated their influence on specific disease…
Abstract Number: 1272 • 2017 ACR/ARHP Annual Meeting
Cluster Analysis of Autoantibodies and Their Relationship with Demographic and Clinical Features in Pediatric Systemic Lupus Erythematosus in the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry
Ginger Janow¹, Uptej Khalsa² and Tracy Andrews³, ¹Pediatric Rheumatology, Joseph M Sanzari Children’s Hospital, Hackensack Meridian Health Network, Hackensack, NJ, ²Pediatrics, Newark Beth Israel Medical Center, Children's Hospital of New Jersey, Newark, NJ, ³Research, Hackensack University Medical Center, Hackensack Meridian Health, Hackensack, NJ
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic, heterogeneous, multisystem autoimmune disease characterized, in part, by the presence of autoantibodies. The spectrum of disease presents…
Abstract Number: 1273 • 2017 ACR/ARHP Annual Meeting
Patient Health Questionnaire-9 Utilization for the Detection of Depression in Adolescents and Young Adults with Lupus Nephritis
Peter Yorgin¹, Eleanor Lazarow² and Robert Sheets³, ¹Pediatrics, Rady Children's Hospital/University of California San Diego, San Diego, CA, ²Social Work, Rady Children's Hospital, San Diego, CA, ³Pediatrics, Rady Children's Hospital/UCSD, San Diego, CA
Background/Purpose: The PHQ-9 is a self-administered depression screening questionnaire. Patients with a PHQ-9 score of 0-4 have no depression, 5-9, mild; 10-14, moderate; 15-19, moderately severe;…
Abstract Number: 1274 • 2017 ACR/ARHP Annual Meeting
Anti-MDA5 Autoantibodies Associated with Juvenile Dermatomyositis Constitute a Distinct Phenotype in North America
Gulnara Mamyrova¹, Takayuki Kishi², Ira N Targoff³, Rodolfo V Curiel⁴, Frederick W Miller² and Lisa G Rider², ¹Rheumatology, George Washington University School of Medicine and Health Sciences, Washington, DC, ²Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ³VA Medical Center, University of Oklahoma Health Sciences Center, and Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴George Washington University School of Medicine and Health Sciences, Washington, DC
Background/Purpose: Anti-MDA5 autoantibodies (Abs) have been associated with clinically amyopathic and classic dermatomyositis (DM), with rapidly progressive interstitial lung disease (ILD) and poor prognosis in…
Abstract Number: 1275 • 2017 ACR/ARHP Annual Meeting
101 Juvenile Myositis Patients Characterized By Myositis Specific Antibodies: Disease Activity and Damage over 60 Months
Lauren M. Pachman^1,2, Megan L. Curran³, Gabrielle A. Morgan⁴, IRA Targoff⁵, Hua Huang⁶, Dong Xu⁷ and Chiang-Ching Huang⁸, ¹Cure JM Program of Excellence in Juvenile Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ²Pediatric Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ³Pediatric Immunology/Rheum, UCSF, San Francisco, CA, ⁴Cure JM Program of Excellence in Myositis Research, Chicago, IL, ⁵internal Medicine, The University of Oklaoma, Norman, OK, ⁶Joseph J. Zilber School of Public Health, Milwaukee, WI, ⁷Pediatric Rheumatology, Stanley Manne Research Center, Chicago, IL, ⁸Biostatistics, Joseph J. Zilber School of Public Health,, Milwaukee, WI
Background/Purpose: The impetus for this investigation was the specific questions from parents of JM patients pertaining to the physician’s expectations about their child’s disease course.…
Abstract Number: 1276 • 2017 ACR/ARHP Annual Meeting
Nail Fold Capillary Changes Are Associated with Pulmonary, but Not with Cardiac Involvement in Juvenile Dermatomyositis
Zoltán Barth^1,2,3, Thomas Schwartz^2,4, Berit Flatø^5,6, Akos Koller^7,8, May Brit Samersaw-Lund⁹, Ivar Sjaastad^10,11 and Helga Sanner⁶, ¹Bjorknes College, Oslo, Norway, ²Oslo University Hospital and University of Oslo, Institute for Experimental Medical Research, Oslo, Norway, ³Medical School, University of Pecs, Institute for Translational Medicine, Pecs, Hungary, ⁴Institute for Experimental Medical Research, Institute for Clinical Medicine, University of Oslo, Oslo, Norway, ⁵Institute for Clinical Medicine, University of Oslo, Oslo, Norway, Oslo, Norway, ⁶Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, Oslo, Norway, ⁷University of Physical Education, Institute of Natural Sciences, Budapest, Hungary, ⁸Medical School, University of Pecs, Department of Neurosurgery, Pecs, Hungary, ⁹Oslo University Hospital, Rikshospitalet, Department of Respiratory Medicine, Oslo, Norway, ¹⁰Department of Cardiology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ¹¹Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Oslo, Norway, Oslo, Norway
Background/Purpose: Juvenile dermatomyositis (JDM) is a rare autoimmune disease of unknown origin, characterised primarily by cutaneous rashes and symmetrical weakness of the proximal skeletal muscles.…
Abstract Number: 1277 • 2017 ACR/ARHP Annual Meeting
Longitudinal Predictors of Physical Function in Juvenile Myositis
Kaveh Ardalan^1,2, Hannah L. Palac^3,4, Julia (Jungwha) Lee⁴, Madison Wolfe^5,6, Gabrielle A. Morgan^7,8 and Lauren M. Pachman⁹, ¹Departments of Pediatrics and Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Division of Rheumatology, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ³Abbvie, Inc, Chicago, IL, ⁴Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵Division of Rheumatology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁶Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁷Cure JM Program of Excellence in Myositis Research, Chicago, IL, ⁸Rheumatology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁹Cure JM Program of Excellence in Juvenile Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL
Background/Purpose: Juvenile myositis (JM) is marked by skin rashes, proximal muscle weakness, and deconditioning causing potentially severe disability. Studies examining long-term physical function in JM…
Abstract Number: 1278 • 2017 ACR/ARHP Annual Meeting
Growth and Puberty in Juvenile Dermatomyositis a Longitudinal Multinatinal Cohort Study
Ellen Nordal^1,2, Angela Pistorio³, Marite Rygg³, Gabriella Giancane⁴, Michaël Hofer³, Jose Antonio Melo-Gomes⁴, Blanca Bica⁴, Ximean Norambuena⁴, Valda Stanevicha³, Rebecca ten Cate⁵, Olga Vougiouka⁴, Jurgen Brunner⁴, Guenther Dannecker⁴, Polyxeni Pratsidou-Gertsi⁴, Gabriele Simonini⁴, Helen Venning⁴, Serena Pastore⁴, Angelo Ravelli⁶, Alberto Martini⁷ and Nicolino Ruperto⁷, ¹Department of Pediatrics, University Hospital of Northern Norway, Tromsø, Norway, ²Department of Clinical medicine, UIT, the Arctic University of Norway, Tromsø, Norway, ³Istituto Giannina Gaslini - Pediatria II, Reumatologia - PRINTO, Genoa, Italy, ⁴Istituto Giannina Gaslini - Pediatria II, Reumatologia - PRINTO, Genova, Italy, ⁵Pediatric Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁶University of Genova, IRCCS Istituto Giannina Gaslini, Genova, Italy, ⁷Istituto Giannina Gaslini, Genoa, Italy
Background/Purpose: Children with juvenile dermatomyositis (JDM) are at risk of growth failure and delayed puberty because of inflammatory disease activity and side effects of corticosteroid…
Abstract Number: 1279 • 2017 ACR/ARHP Annual Meeting
Risk Factors for Achieving a Drug-Free Remission in Patients with Juvenile Dermatomyositis
Tomokazu Nagakura¹, Takuma Ito², Masateru Kusuda², Tuyoshi Yamatou², Tomohiro Kubota², Yuuichi Yamasaki², Yukiko Nonaka², Tomoko Takezaki², Harumi Akaike³, Yasuhito Nerome², Hiroyuki Imanaka² and Syuji Takei⁴, ¹Pediatrics, The Holy Mother of Grace Hospital Home for Children and Persons with Severe Motor and Intellectual Disabilities, Usuki, Japan, Usuki, Japan, ²Department of Pediatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan, Kagoshima, Japan, ³Department of Pediatrics, Department of Pediatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan, Kagoshima, Japan, ⁴Department of Pediatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan, Kagoshma, Japan
Background/Purpose: Juvenile dermatomyositis (JDM) is the most common idiopathic inflammatory myopathy in children. Approximately one-third of JDM patients attain drug-free remission (DFR) without relapse; however,…
Abstract Number: 1280 • 2017 ACR/ARHP Annual Meeting
Clinical Outcomes of Juvenile Dermatomyositis Patients Treated with TNF-Inhibitors: A Retrospective Chart Review Katelyn Banschbach1, Ellen Go1 and Stacey Tarvin2, 1Indiana University School of Medicine, 2riley Hospital for Children, Indiana University
Katelyn Banschbach¹, Ellen Go² and Stacey Tarvin³, ¹Indiana University School of Medicine, Indianapolis, IN, ²Pediatrics, Indiana University School of Medicine, Indianapolis, IN, ³Riley Hospital for Children, Indiana University, Indianapolis, IN
Background/Purpose: To analyze the clinical outcomes of TNF-inhibitors as a steroid-sparing agent in the treatment of juvenile dermatomyositis (JDM). Methods: We performed a retrospective chart…
Abstract Number: 1281 • 2017 ACR/ARHP Annual Meeting
Plasma CXCL4 As a Biomarker in Juvenile Systemic Sclerosis
Katharine Moore^1,2, Marvin J. Fritzler³, Marisa S. Klein-Gitelman⁴, Ann M Reed⁵, Tzielan Lee⁶ and Anne Stevens^7,8, ¹Pediatrics, University of Colorado, Aurora, CO, ²Pediatric Rheumatology, Children's Hospital Colorado, Aurora, CO, ³Medicine, University of Calgary, Calgary, AB, Canada, ⁴Division of Pediatric Rheumatology/PDD PTD, Lurie Children's Hospital of Chicago/Northwestern University, Chicago, IL, ⁵Rheumatology, Duke University, Durham, NC, ⁶Pediatric Rheumatology, Stanford University, Palo Alto, CA, ⁷University of Washington, Department of Pediatrics, Seattle, WA, ⁸Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA
Background/Purpose: Juvenile systemic sclerosis (jSSc) is a severe and heterogeneous autoimmune vasculopathy. Pulmonary fibrosis is the highest independent predictor of mortality, yet currently there are…
Abstract Number: 1282 • 2017 ACR/ARHP Annual Meeting
Assessing the Prevalence of Juvenile Systemic Sclerosis in Childhood Using Administrative Claims Data from the United States
Ivan Foeldvari¹, Timothy Beukelman² and Fenglong Xie³, ¹Hamburg Center for Pediatric and Adolescent Rheumatology, Hamburg, Germany, ²Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Juvenile systemic Sclerosis (jSSc) is an orphan disease. There are some data regarding the incidence, but nearly no data exist regarding the prevalence of…
Abstract Number: 1283 • 2017 ACR/ARHP Annual Meeting
Male Patients Have a More Severe Course As Female Patients with Diffuse Juvenile Systemic Scleroderma? Results from the Juvenile Scleroderma Inception Cohort Www.Juvenile-Scleroderma.Com
Ivan Foeldvari¹, Jens Klotsche², Ozgur Kasapcopur³, Amra Adrovic⁴, Valda Stanevicha⁵, Maria Teresa Terreri⁶, Ekaterina Alexeeva⁷, Maria M. Katsicas⁸, Vanessa Smith⁹, Rolando Cimaz¹⁰, Mikhail Kostik¹¹, Thomas J. A. Lehman¹², Jordi Anton¹³, Walter A. Sifuentes-Giraldo¹⁴, Flavio Sztajnbok¹⁵, Tadey Avcin¹⁶, Mahesh Janarthanan¹⁷, Maria José Santos¹⁸, Dana Nemkova¹⁹, Cristina Battagliotti²⁰, Despina Eleftheriou²¹, Liora Harel²², Tilmann Kallinich²³, K Minden²⁴, Susan Mary Nielsen²⁵, Kathryn S. Torok²⁶, Yosef Uziel²⁷, Anne Stevens²⁸, Clarissa Pilkington²⁹ and Nicola Helmus¹, ¹Hamburg Center for Pediatric and Adolescent Rheumatology, Hamburg, Germany, ²Epidemiology unit, German Rheumatism Research Center, Berlin, Germany, ³Pediatric Rheumatology, Istanbul University, Cerrahpasa Medical School, Department of Pediatric Rheumatology, Istanbul, Turkey, ⁴Department of Pediatric Rheumatology, Istanbul University, Cerrahpasa Medical School, Istanbul, Turkey, ⁵Pediatric cathedra, Riga Stradiņš University, Riga, Latvia, ⁶Pediatric Rheumatology Unit, Federal University of São Paulo (UNIFESP - Universidade Federal de São Paulo), São Paulo, Brazil, ⁷Children's Health of RAMS and IM Sechenov First Moscow State Medical University, Moscow, Russian Federation, ⁸Service of Immunology & Rheumatology., Hospital de Pediatría Prof Dr JP Garrahan, Buenos Aires, Argentina, ⁹Faculty of Internal Medicine, Ghent University, Ghent, Belgium, ¹⁰Pediatrics, Ospedale Pediatrico Anna Meyer, Florence, Italy, ¹¹Hospital Pediatrics, State Pediatric Medical University, Saint-Petersburg, Russia, ¹²Pediatric Rheumatology, Hospital for Special Surgery Weill Cornell Medical College, New York, NY, ¹³pediatric Rheumatology, University Childrenxs Hospital, Barcelona, Spain, ¹⁴Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain, ¹⁵Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, ¹⁶University Children's Hospital, Ljubljana, Slovenia, ¹⁷Pediatric Rheumatology, Chennai, India, ¹⁸Reuma.pt, Almada, Portugal, Almada, Portugal, ¹⁹Pediatric Rheumatology Unit, Department of Pediatrics and Adolescent Medicine, General University Hospital in Prague, Prague, Czech Republic, ²⁰Hospital de Niños Dr Orlando Alasia, Santa Fé, Argentina, ²¹Infection, Inflammation and Rheumatology, UCL Institute of Child Health, London, United Kingdom, ²²Schneider Children's Medical Center of Israel, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel, ²³Charité, Humbolt University Medicine Berlin, Berlin, Germany, ²⁴Charité – University of Medicine Berlin, Berlin, Germany, ²⁵Rigshospitalet, Copenhagen, Denmark, ²⁶Pediatric Rheumatology, University of Pittsburgh Med Ctr, Pittsburgh, PA, ²⁷Meir Medical Center, Kfar Saba, Israel, ²⁸University of Washington, Department of Pediatrics, Seattle, WA, ²⁹Paediatric Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom
Background/Purpose: In adult systemic scleroderma patients male have a more sever course. This issue was never evaluated in a larger juvenile scleroderma cohort. Methods: Patients…
Abstract Number: 1284 • 2017 ACR/ARHP Annual Meeting
The Localized Scleroderma Quality of Life Instrument (LoSQI): Initial Validation in Pediatric Localized Scleroderma
Christina K. Zigler¹, Kaveh Ardalan², Kaila Schollaert-Fitch³, Heidi Jacobe⁴ and Kathryn S. Torok³, ¹Physical Medicine & Rehabilitation, University of Pittsburgh, Pittsburgh, PA, ²Division of Rheumatology, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ³Pediatric Rheumatology, University of Pittsburgh Med Ctr, Pittsburgh, PA, ⁴Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: There is a current need to integrate health related quality of life (HRQoL) into outcomes for clinical trials (Chang & Reeve, 2005). For pediatric…
Abstract Number: 1285 • 2017 ACR/ARHP Annual Meeting
Extracutaneous Involvement Is Common in Juvenile Localized Scleroderma and Associated with a Higher Level of Perceived Disease Impact
Suzanne C. Li¹, Tracy Andrews², Mallory Chen³, Kathryn S. Torok⁴, Elena Pope⁵, Katie G. Stewart⁶, Gloria C. Higgins⁷, C. Egla Rabinovich⁸, Ronald M. Laxer⁹, Kathleen Haines¹⁰, Marilynn Punaro¹¹, Heidi Jacobe¹² and Kathleen O'Neil¹³, ¹Pediatrics, Joseph M Sanzari Children's Hospital, Hackensack Meridian Health, Hackensack, NJ, ²Research, Hackensack University Medical Center, Hackensack Meridian Health, Hackensack, NJ, ³Williams College, williamstown, MA, ⁴Pediatric Rheumatology, University of Pittsburgh Med Ctr, Pittsburgh, PA, ⁵Section of Dermatology, The Hospital for Sick Children, Hospital for Sick Children, Toronto, ON, Canada, ⁶Pediatric Rheumatology, Texas Scottish Rite Hospital, Dallas, TX, ⁷Pediatric Rheumatology Ohio State University, Nationwide Childrens Hospital, Columbus, OH, ⁸Pediatric Rheumatology, Duke University Medical Center, Durham, NC, ⁹Div of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ¹⁰Joseph M Sanzari Children’s Hospital, Hackensack Meridian Health, Hackensack, NJ, ¹¹Texas Scottish Rite Hospital for Children, Dallas, TX, ¹²Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, TX, ¹³Pediatric Rheumatology, RIley Hospital for Children, Indianapolis, IN
Background/Purpose: Juvenile localized scleroderma (jLS) is often associated with deep tissue and extracutaneous involvement (ECI), putting children at risk for severe morbidity such as hemiatrophy,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].